Currently, there are 74.05M common shares owned by the public and among those 54.06M shares have been available to trade.
The company’s stock has a 5-day price change of 28.75% and 31.49% over the past three months. CATX shares are trading -3.13% year to date (YTD), with the 12-month market performance down to -76.59% lower. It has a 12-month low price of $1.60 and touched a high of $16.55 over the same period. CATX has an average intraday trading volume of 759.73K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.94%, 34.28%, and -51.07% respectively.
Institutional ownership of Perspective Therapeutics Inc (AMEX: CATX) shares accounts for 66.43% of the company’s 74.05M shares outstanding.
It has a market capitalization of $229.37M and a beta (3y monthly) value of 1.13. The earnings-per-share (ttm) stands at -$1.21. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.01% over the week and 9.34% over the month.
Analysts forecast that Perspective Therapeutics Inc (CATX) will achieve an EPS of -0.29 for the current quarter, -0.31 for the next quarter and -1.29 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.33 while analysts give the company a high EPS estimate of -0.33. Earnings per share for the fiscal year are expected to increase by 6.46%, and -12.06% over the next financial year. EPS should grow at an annualized rate of -1.94% over the next five years, compared to -9.86% over the past 5-year period.
Looking at the support for the CATX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on March 13, 2025, with the firm’s price target at $10. Scotiabank coverage for the Perspective Therapeutics Inc (CATX) stock in a research note released on March 07, 2025 offered a Sector Outperform rating with a price target of $15. BofA Securities was of a view on November 25, 2024 that the stock is Neutral, while UBS gave the stock Buy rating on October 24, 2024, issuing a price target of $20. Wedbush on their part issued Outperform rating on October 01, 2024.
